90Y Ibritumomab tiuxetan

DRUG2 trials

Sponsors

Stanford University, The Christie NHS Foundation Trust

Conditions

Blood and Marrow Transplant (BMT)Follicular LymphomaLymphoma, Non-Hodgkin

Phase 1

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

CompletedNCT00186589

Stanford UniversityBlood and Marrow Transplant (BMT), Lymphoma, Non-Hodgkin

Start: 2004-05-31End: 2007-07-31Target: 30Updated: 2012-06-06

Phase 2

Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma

CompletedNCT01493479

The Christie NHS Foundation TrustFollicular Lymphoma

Start: 2007-06-06End: 2015-11-06Updated: 2019-10-15